Amendment No. 7 to Schedule 13D by Fairmount Funds Management LLC

Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC filed Amendment No. 7 to their Schedule 13D regarding their holdings in Viridian Therapeutics, Inc. The amendment reports that Fairmount Funds Management LLC, through its investment in Fairmount Healthcare Fund II LP, now holds 16,025,330 shares of Common Stock, representing a 15.14% ownership stake. This includes 3,914,458 shares of Common Stock and 12,110,872 shares issuable upon conversion of Series A and Series B Preferred Stock. The amendment also details a recent purchase of 454,545 shares of Common Stock at $22 per share, totaling $9,999,990.00, in an underwritten public offering. The filing includes a Lock-Up Agreement restricting the sale of shares for 60 days post-offering. The amendment underscores the investment purpose behind these transactions and the shared voting and dispositive power over the shares.